论文部分内容阅读
目的:观察扶脾柔肝方配方颗粒对肝纤维化大鼠肝组织诱导型一氧化氮合酶(i NOS)表达的影响,并探讨其作用机制。方法:SD大鼠按随机数字表法分为正常组、模型组、秋水仙碱(0.2 mg·kg-1)组、扶正化瘀(0.415 g·kg-1)组、扶脾柔肝方配方颗粒高、中、低剂量(80,40,20 g·kg-1)组,采用四氯化碳复合乙醇诱导大鼠肝纤维化模型,造模8周成功后,分别给予相应药物ig,每日1次,连续4周,正常组、模型组ig等体积生理盐水。第12周末,检测大鼠血清丙氨酸氨基转移酶(ALT),天门冬氨酸氨基酸转移酶(AST),透明质酸(HA);苏木素伊红(HE)染色观察肝组织病理情况;采用实时荧光定量PCR(Realtime PCR)及免疫印迹法(Western blot)检测大鼠肝组织i NOS mRNA和蛋白表达水平。结果:与正常组比较,模型组大鼠血清中ALT,AST,HA含量显著升高(P<0.01);与模型组比较,秋水仙碱组、扶正化瘀组、扶脾柔肝方低、中剂量组血清中的ALT,AST含量均明显降低(P<0.05),高剂量组ALT,AST含量显著降低(P<0.01),秋水仙碱组、扶正化瘀组、扶脾柔肝方中剂量组血清中的HA含量明显降低(P<0.05),扶脾柔肝方高剂量组HA含量显著降低(P<0.01)。与模型组比较,各药物干预组肝组织内纤维化程度均有不同程度减轻(P<0.05)。与正常组比较,模型组大鼠肝组织i NOS mRNA和蛋白表达显著升高(P<0.01);与模型组比较,各药物干预组大鼠肝组织i NOS mRNA和蛋白表达显著降低(P<0.01),其中以扶脾柔肝方高剂量组最明显。结论:扶脾柔肝方配方颗粒下调纤维化肝组织i NOS mRNA和蛋白表达水平,可能是其抗肝纤维化作用机制之一。
Objective: To observe the effect of Fufang Rougan Prescription Granules on the expression of inducible nitric oxide synthase (iNOS) in liver tissue of rats with hepatic fibrosis and to explore its mechanism. Methods: SD rats were randomly divided into normal group, model group, colchicine 0.2 mg · kg -1, Fuzhenghuayu 0.415 g · kg -1, The rats in high, medium and low dose groups (80, 40, 20 g · kg -1) were induced with carbon tetrachloride and ethanol to induce hepatic fibrosis. After 8 weeks of successful model establishment, Day 1, for 4 weeks, normal group, model group ig equal volume of saline. At the end of the twelfth week, serum alanine aminotransferase (ALT), aspartate aminotransferase (AST), and hyaluronic acid (HA) were detected in rats. Liver histopathology was observed by hematoxylin eosin staining. Real-time PCR and Western blot were used to detect the expression of iNOS mRNA and protein in rat liver tissue. Results: Compared with the normal group, the contents of ALT, AST and HA in the model group were significantly increased (P <0.01). Compared with the model group, the concentrations of colchicine, Fuzhenghuayu, The contents of ALT and AST in the middle-dose group were significantly decreased (P <0.05), while the levels of ALT and AST in the high-dose group were significantly decreased (P <0.01). In the colchicine group, Fuzhenghuayu group, The content of HA in the serum of the dose group was significantly lower (P <0.05), and the content of HA in the high dose of the recipe of Fu - spleen Rougan formula was significantly lower (P <0.01). Compared with the model group, the degree of fibrosis in the liver tissue of each drug intervention group was relieved to varying degrees (P <0.05). Compared with normal group, the expression of iNOS mRNA and protein in liver tissue of model group was significantly increased (P <0.01). Compared with model group, the expression of iNOS mRNA and protein in liver tissue of each model group was significantly decreased (P < 0.01), among which the high dose of Fufang Rougan prescription was the most obvious. Conclusion: Fufang Rougan decoction can down-regulate the expression of iNOS mRNA and protein in fibrotic liver tissue, which may be one of its mechanisms of anti-liver fibrosis.